BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Taskar KS, Pilla Reddy V, Burt H, Posada MM, Varma M, Zheng M, Ullah M, Emami Riedmaier A, Umehara KI, Snoeys J, Nakakariya M, Chu X, Beneton M, Chen Y, Huth F, Narayanan R, Mukherjee D, Dixit V, Sugiyama Y, Neuhoff S. Physiologically-Based Pharmacokinetic Models for Evaluating Membrane Transporter Mediated Drug-Drug Interactions: Current Capabilities, Case Studies, Future Opportunities, and Recommendations. Clin Pharmacol Ther 2020;107:1082-115. [PMID: 31628859 DOI: 10.1002/cpt.1693] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 9.0] [Reference Citation Analysis]
Number Citing Articles
1 Djebli N, Buchheit V, Parrott N, Guerini E, Cleary Y, Fowler S, Frey N, Yu L, Mercier F, Phipps A, Meneses-Lorente G. Physiologically-Based Pharmacokinetic Modelling of Entrectinib Parent and Active Metabolite to Support Regulatory Decision-Making. Eur J Drug Metab Pharmacokinet 2021. [PMID: 34495458 DOI: 10.1007/s13318-021-00714-z] [Reference Citation Analysis]
2 Abbiati RA, Wientjes MG, Au JL. Is It Time to Use Modeling of Cellular Transporter Homeostasis to Inform Drug-Drug Interaction Studies: Theoretical Considerations. AAPS J 2021;23:102. [PMID: 34435271 DOI: 10.1208/s12248-021-00635-4] [Reference Citation Analysis]
3 Bolleddula J, Ke A, Yang H, Prakash C. PBPK modeling to predict drug-drug interactions of ivosidenib as a perpetrator in cancer patients and qualification of the Simcyp platform for CYP3A4 induction. CPT Pharmacometrics Syst Pharmacol 2021;10:577-88. [PMID: 33822485 DOI: 10.1002/psp4.12619] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
4 Humphreys SC, Davis JA, Iqbal S, Kamel A, Kulmatycki K, Lao Y, Liu X, Rodgers J, Snoeys J, Vigil A, Weng Y, Wiethoff CM, Wittwer MB. Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics. Nucleic Acids Res 2022:gkac456. [PMID: 35687098 DOI: 10.1093/nar/gkac456] [Reference Citation Analysis]
5 Jala A, Ponneganti S, Vishnubhatla DS, Bhuvanam G, Mekala PR, Varghese B, Radhakrishnanand P, Adela R, Murty US, Borkar RM. Transporter-mediated drug-drug interactions: advancement in models, analytical tools, and regulatory perspective. Drug Metab Rev 2021;:1-36. [PMID: 33980079 DOI: 10.1080/03602532.2021.1928687] [Reference Citation Analysis]
6 Peng Y, Cheng Z, Xie F. Evaluation of Pharmacokinetic Drug-Drug Interactions: A Review of the Mechanisms, In Vitro and In Silico Approaches. Metabolites 2021;11:75. [PMID: 33513941 DOI: 10.3390/metabo11020075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
7 Mochizuki T, Mizuno T, Maeda K, Kusuhara H. Current progress in identifying endogenous biomarker candidates for drug transporter phenotyping and their potential application to drug development. Drug Metab Pharmacokinet 2021;37:100358. [PMID: 33461054 DOI: 10.1016/j.dmpk.2020.09.003] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Yin J, Li F, Zhou Y, Mou M, Lu Y, Chen K, Xue J, Luo Y, Fu J, He X, Gao J, Zeng S, Yu L, Zhu F. INTEDE: interactome of drug-metabolizing enzymes. Nucleic Acids Res 2021;49:D1233-43. [PMID: 33045737 DOI: 10.1093/nar/gkaa755] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 7.0] [Reference Citation Analysis]
9 Liu C, Zhou S, Bai W, Shi L, Li X. Protective effect of food derived nutrients on cisplatin nephrotoxicity and its mechanism. Food Funct 2022;13:4839-60. [PMID: 35416186 DOI: 10.1039/d1fo04391a] [Reference Citation Analysis]
10 Chu X, Chan GH, Houle R, Lin M, Yabut J, Fandozzi C. In Vitro Assessment of Transporter Mediated Perpetrator DDIs for Several Hepatitis C Virus Direct-Acting Antiviral Drugs and Prediction of DDIs with Statins Using Static Models. AAPS J 2022;24. [DOI: 10.1208/s12248-021-00677-8] [Reference Citation Analysis]
11 Al-Majdoub ZM, Achour B, Couto N, Howard M, Elmorsi Y, Scotcher D, Alrubia S, El-Khateeb E, Vasilogianni AM, Alohali N, Neuhoff S, Schmitt L, Rostami-Hodjegan A, Barber J. Mass spectrometry-based abundance atlas of ABC transporters in human liver, gut, kidney, brain and skin. FEBS Lett 2020;594:4134-50. [PMID: 33128234 DOI: 10.1002/1873-3468.13982] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
12 Wei J, Liu R, Zhang J, Liu S, Yan D, Wen X, Tian X. Baicalin Enhanced Oral Bioavailability of Sorafenib in Rats by Inducing Intestine Absorption. Front Pharmacol 2021;12:761763. [PMID: 34819863 DOI: 10.3389/fphar.2021.761763] [Reference Citation Analysis]
13 Pan X, Yamazaki S, Neuhoff S, Zhang M, Pilla Reddy V. Unraveling pleiotropic effects of rifampicin by using physiologically based pharmacokinetic modeling: Assessing the induction magnitude of P-glycoprotein-cytochrome P450 3A4 dual substrates. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34729944 DOI: 10.1002/psp4.12717] [Reference Citation Analysis]
14 Harwood MD, Rostami‐hodjegan A, Neuhoff S. APPLICATION OF PHYSIOLOGICALLY BASED PHARMACOKINETIC AND PHARMACODYNAMIC (PBPK/PD) MODELING COMPRISING TRANSPORTERS. In: You G, Morris ME, editors. Drug Transporters. Wiley; 2022. pp. 475-96. [DOI: 10.1002/9781119739883.ch23] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Arora S, Pansari A, Kilford PJ, Jamei M, Turner DB, Gardner I. A Mechanistic Absorption and Disposition Model of Ritonavir to Predict Exposure and Drug-Drug Interaction Potential of CYP3A4/5 and CYP2D6 Substrates. Eur J Drug Metab Pharmacokinet 2022. [PMID: 35486324 DOI: 10.1007/s13318-022-00765-w] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
16 Pilla Reddy V, El-Khateeb E, Jo H, Giovino N, Lythgoe E, Sharma S, Tang W, Jamei M, Rastomi-Hodjegan A. Pharmacokinetics under the COVID-19 storm. Br J Clin Pharmacol 2020. [PMID: 33226664 DOI: 10.1111/bcp.14668] [Reference Citation Analysis]
17 Otsuka Y, Choules MP, Bonate PL, Komatsu K. Physiologically-Based Pharmacokinetic Modeling for the Prediction of a Drug-Drug Interaction of Combined Effects on P-glycoprotein and Cytochrome P450 3A. CPT Pharmacometrics Syst Pharmacol 2020;9:659-69. [PMID: 33030266 DOI: 10.1002/psp4.12562] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
18 Weiss HM, Umehara KI, Erpenbeck VJ, Cain M, Vemula J, Elbast W, Zollinger M. A Study of the Effect of Cyclosporine on Fevipiprant Pharmacokinetics and its Absolute Bioavailability Using an Intravenous Microdose Approach. Drug Metab Dispos 2020;48:917-24. [PMID: 32739890 DOI: 10.1124/dmd.120.090852] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
19 Alluri RV, Li R, Varma MVS. Transporter–enzyme interplay and the hepatic drug clearance: what have we learned so far? Expert Opinion on Drug Metabolism & Toxicology 2020;16:387-401. [DOI: 10.1080/17425255.2020.1749595] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
20 Sharma S, Suresh Ahire D, Prasad B. Utility of Quantitative Proteomics for Enhancing the Predictive Ability of Physiologically Based Pharmacokinetic Models Across Disease States. The Journal of Clinical Pharmacology 2020;60. [DOI: 10.1002/jcph.1709] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
21 Martinez MN, Sinko B, Wu F, Flanagan T, Borbás E, Tsakalozou E, Giacomini KM. A Critical Overview of the Biological Effects of Excipients (Part I): Impact on Gastrointestinal Absorption. AAPS J 2022;24. [DOI: 10.1208/s12248-022-00711-3] [Reference Citation Analysis]
22 Chen Y, Ma F, Jones NS, Yoshida K, Chiang PC, Durk MR, Wright MR, Jin JY, Chinn LW. Physiologically-Based Pharmacokinetic Model-Informed Drug Development for Fenebrutinib: Understanding Complex Drug-Drug Interactions. CPT Pharmacometrics Syst Pharmacol 2020;9:332-41. [PMID: 32383787 DOI: 10.1002/psp4.12515] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
23 Lin W, Chen Y, Unadkat JD, Zhang X, Wu D, Heimbach T. Applications, Challenges, and Outlook for PBPK Modeling and Simulation: A Regulatory, Industrial and Academic Perspective. Pharm Res 2022. [PMID: 35552967 DOI: 10.1007/s11095-022-03274-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
24 Yamazaki S, Evers R, De Zwart L. Physiologically-based pharmacokinetic modeling to evaluate in vitro-to-in vivo extrapolation for intestinal P-glycoprotein inhibition. CPT Pharmacometrics Syst Pharmacol 2021. [PMID: 34668334 DOI: 10.1002/psp4.12733] [Reference Citation Analysis]
25 Giacomini KM. Novel Technologies Enable Mechanistic Understanding and Modeling of Drug Exposure and Response. Clin Pharmacol Ther 2020;107:1045-7. [PMID: 32304600 DOI: 10.1002/cpt.1822] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
26 Lai Y, Chu X, Di L, Gao W, Guo Y, Liu X, Lu C, Mao J, Shen H, Tang H, Xia CQ, Zhang L, Ding X. Recent advances in the translation of drug metabolism and pharmacokinetics science for drug discovery and development. Acta Pharmaceutica Sinica B 2022;12:2751-77. [DOI: 10.1016/j.apsb.2022.03.009] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
27 Venkatakrishnan K, van der Graaf PH. Model-Informed Drug Development: Connecting the Dots With a Totality of Evidence Mindset to Advance Therapeutics. Clin Pharmacol Ther 2021;110:1147-54. [PMID: 34658027 DOI: 10.1002/cpt.2422] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Pilla Reddy V, Jo H, Neuhoff S. Food constituent- and herb-drug interactions in oncology: Influence of quantitative modelling on Drug labelling. Br J Clin Pharmacol 2021;87:3988-4000. [PMID: 33733472 DOI: 10.1111/bcp.14822] [Reference Citation Analysis]
29 Izat N, Sahin S. Hepatic transporter-mediated pharmacokinetic drug-drug interactions: Recent studies and regulatory recommendations. Biopharm Drug Dispos 2021;42:45-77. [PMID: 33507532 DOI: 10.1002/bdd.2262] [Reference Citation Analysis]
30 Pilla Reddy V, Fretland AJ, Zhou D, Sharma S, Chen B, Vishwanathan K, McGinnity DF, Xu Y, Ware JA. Mechanistic physiology-based pharmacokinetic modeling to elucidate vincristine-induced peripheral neuropathy following treatment with novel kinase inhibitors. Cancer Chemother Pharmacol 2021;88:451-64. [PMID: 34080039 DOI: 10.1007/s00280-021-04302-5] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
31 Braeuning A, Bloch D, Karaca M, Kneuer C, Rotter S, Tralau T, Marx-stoelting P. An approach for mixture testing and prioritization based on common kinetic groups. Arch Toxicol. [DOI: 10.1007/s00204-022-03264-8] [Reference Citation Analysis]
32 Kulkarni PR, Youssef AS, Argikar AA. Prediction of Drug Clearance from Enzyme and Transporter Kinetics. Methods Mol Biol 2021;2342:369-417. [PMID: 34272702 DOI: 10.1007/978-1-0716-1554-6_14] [Reference Citation Analysis]
33 Taskar KS, Yang X, Neuhoff S, Patel M, Yoshida K, Paine MF, Brouwer KLR, Chu X, Sugiyama Y, Cook J, Polli JW, Hanna I, Lai Y, Zamek-Gliszczynski M; ITC. Clinical Relevance of Hepatic and Renal P-gp/BCRP Inhibition of Drugs: An International Transporter Consortium Perspective. Clin Pharmacol Ther 2022. [PMID: 35612761 DOI: 10.1002/cpt.2670] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
34 Zhang X, Yang Y, Grimstein M, Fan J, Grillo JA, Huang SM, Zhu H, Wang Y. Application of PBPK Modeling and Simulation for Regulatory Decision Making and Its Impact on US Prescribing Information: An Update on the 2018-2019 Submissions to the US FDA's Office of Clinical Pharmacology. J Clin Pharmacol 2020;60 Suppl 1:S160-78. [PMID: 33205429 DOI: 10.1002/jcph.1767] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 13.0] [Reference Citation Analysis]
35 Jin Z, He Q, Zhu X, Zhu M, Wang Y, Wu XA, Lv Q, Xiang X. Application of physiologically based pharmacokinetic modelling for the prediction of drug-drug interactions involving anlotinib as a perpetrator of cytochrome P450 enzymes. Basic Clin Pharmacol Toxicol 2022;130:592-605. [PMID: 35289081 DOI: 10.1111/bcpt.13721] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Chu X, Prasad B, Neuhoff S, Yoshida K, Leeder JS, Mukherjee D, Taskar K, Varma MVS, Zhang X, Yang X, Galetin A. Clinical Implications of Altered Drug Transporter Abundance/Function and PBPK Modeling in Specific Populations: An ITC Perspective. Clin Pharmacol Ther 2022. [PMID: 35561140 DOI: 10.1002/cpt.2643] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
37 Tess DA, Kimoto E, King-Ahmad A, Vourvahis M, Rodrigues AD, Bergman A, Qui R, Somayaji V, Weng Y, Fonseca KR, Litchfield J, Varma MVS. Effect of a Ketohexokinase Inhibitor (PF-06835919) on In Vivo OATP1B Activity: Integrative Risk Assessment Using Endogenous Biomarker and a Probe Drug. Clin Pharmacol Ther 2022. [PMID: 35355249 DOI: 10.1002/cpt.2593] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
38 Lang J, Vincent L, Chenel M, Ogungbenro K, Galetin A. Reduced physiologically-based pharmacokinetic model of dabigatran etexilate-dabigatran and its application for prediction of intestinal P-gp-mediated drug-drug interactions. Eur J Pharm Sci 2021;165:105932. [PMID: 34260894 DOI: 10.1016/j.ejps.2021.105932] [Reference Citation Analysis]
39 Xu H, Zhang Y, Wang P, Zhang J, Chen H, Zhang L, Du X, Zhao C, Wu D, Liu F, Yang H, Liu C. A comprehensive review of integrative pharmacology-based investigation: A paradigm shift in traditional Chinese medicine. Acta Pharm Sin B 2021;11:1379-99. [PMID: 34221858 DOI: 10.1016/j.apsb.2021.03.024] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 16.0] [Reference Citation Analysis]
40 Chang M, Bathena S, Christopher LJ, Shen H, Roy A. Prediction of drug-drug interaction potential mediated by transporters between dasatinib and metformin, pravastatin, and rosuvastatin using physiologically based pharmacokinetic modeling. Cancer Chemother Pharmacol 2022. [PMID: 35147740 DOI: 10.1007/s00280-021-04394-z] [Reference Citation Analysis]
41 Dujic T, Cvijic S, Elezovic A, Bego T, Imamovic Kadric S, Malenica M, Elezovic A, Pearson ER, Kulo A. Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. J Pers Med 2021;11:367. [PMID: 34063566 DOI: 10.3390/jpm11050367] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
42 Huttunen KM, Terasaki T, Urtti A, Montaser AB, Uchida Y. Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery. Pharm Res 2022. [PMID: 35257288 DOI: 10.1007/s11095-022-03193-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Bowman CM, Ma F, Mao J, Chen Y. Examination of Physiologically-Based Pharmacokinetic Models of Rosuvastatin. CPT Pharmacometrics Syst Pharmacol 2021;10:5-17. [PMID: 33220025 DOI: 10.1002/psp4.12571] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]